Efficacy and Safety of Sugammadex (2mg/kg) to Shorten Time-to-extubation Among Postoperative ICU Patients Following AVR, CABG Surgery, or AVR/CABG Surgery- a Prospective Randomized Placebo-controlled Trial.
Phase of Trial: Phase IV
Latest Information Update: 03 Sep 2018
Price : $35 *
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 08 Nov 2017 Status changed from not yet recruiting to recruiting.
- 28 Jun 2017 New trial record